F
Franz Dotzer
Researcher at Ludwig Maximilian University of Munich
Publications - 29
Citations - 4275
Franz Dotzer is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Abciximab & Percutaneous coronary intervention. The author has an hindex of 20, co-authored 29 publications receiving 4168 citations.
Papers
More filters
Journal ArticleDOI
Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial
Adnan Kastrati,Julinda Mehilli,Josef Dirschinger,Franz Dotzer,Helmut Schühlen,Franz-Josef Neumann,Martin Fleckenstein,Conrad Pfafferott,Melchior Seyfarth,Albert Schömig +9 more
TL;DR: When two stents with different design are compared, the stent with thinner struts elicits less angiographic and clinical restenosis than the thicker-strut stent.
Journal ArticleDOI
Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment: The ISAR-REACT 2 Randomized Trial
Adnan Kastrati,Julinda Mehilli,Franz-Josef Neumann,Franz Dotzer,Jurriën M. ten Berg,Hildegard Bollwein,Isolde Graf,Maryam Ibrahim,Jürgen Pache,Melchior Seyfarth,Helmut Schühlen,Josef Dirschinger,Peter B. Berger,Albert Schömig,Antithrombotic Regimen: Rapid Early Action for Coronary Treatment Trial Investigators +14 more
TL;DR: In this paper, the role of the glycoprotein IIb/IIIa inhibitor abciximab in patients with non-ST-segment elevation acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) after pretreatment with 600 mg of clopidogrel.
Journal ArticleDOI
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Adnan Kastrati,Julinda Mehilli,Helmut Schühlen,Josef Dirschinger,Franz Dotzer,Jurriën M. ten Berg,Franz-Josef Neumann,Hildegard Bollwein,Christian Volmer,Meinrad Gawaz,Peter B. Berger,Albert Schömig +11 more
TL;DR: The data suggest that in patients at low-to-intermediate risk who undergo elective percutaneous coronary intervention after pretreatment with a high loading dose of clopidogrel, abciximab is associated with no clinically measurable benefit within the first 30 days.
Journal Article
[Intracoronary Stenting and Angiographic Results Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial].
Adnan Kastrati,Julinda Mehilli,Josef Dirschinger,Franz Dotzer,Helmut Schühlen,Franz-Josef Neumann,Martin Fleckenstein,Conrad Pfafferott,Melchior Seyfarth,Albert Schömig +9 more
TL;DR: The use of a thinner-strut device is associated with a significant reduction of angiographic and clinical restenosis after coronary artery stenting, and may have relevant implications for the currently most widely used percutaneous coronary intervention.
Journal ArticleDOI
Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.
Julinda Mehilli,Adnan Kastrati,Stefanie Schulz,Stefan Früngel,Stephan G. Nekolla,Werner Moshage,Franz Dotzer,Kurt Huber,Jürgen Pache,Josef Dirschinger,Melchior Seyfarth,Stefan Martinoff,Markus Schwaiger,Albert Schömig +13 more
TL;DR: Upstream administration of abciximab is not associated with a reduction in infarct size in patients presenting with acute myocardial infarction within 24 hours of symptom onset and receiving 600 mg clopidogrel.